Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

post

Bergqvist P, Burke A, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2024

POSTER IMAGE TO GO HERE.

This poster describes AbCellera’s T-cell engager (TCE) platform, including tailored design strategies to generate optimized TCEs. A panel of novel CD3-binding antibodies are used to widen the therapeutic window by generating TCEs with potent tumor cell-killing and optimal cytokine release. Efficacy of molecules may be enhanced by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB. Finally, data is presented on the application of this platform to AbCellera’s B7-H4 and PSMA TCE programs, with preclinical characterization of TCEs showing tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks.

DOI: 10.1136/jitc-2024-SITC2024.1291

Download poster

Further reading:

  1. Lam K, et al. Cancer Res (2024) 84 (6_Supplement): 1859.
  2. de Puyraimond V, et al. Cancer Res (2024) 84 (6_Supplement): 6359.
  3. Mai M, et al. Cancer Res (2024) 84 (6_Supplement): 1868. 
  4. Mai M, et al. J Immunother Cancer 2023;11(Suppl 1):A1–A1731. 
  5. Mai M, et al. Cancer Res (2023) 83 (7_Supplement): 1886. 
  6. DeVorkin L, et al. Cancer Res (2022) 82 (12_Supplement): 312. 
  7. DeVorkin L, et al. J Immunother Cancer (2022)10 (Suppl 2):A1–A1603.